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analyze cell viability and identify the impact of Luteolin on angiogenesis. Critical components in the Notch pathway including proteins and mRNAs were detected by Western blotting analyses, ELISA assays and real-time reverse transcription-polymerase chain reaction. Matrix metalloproteinases activity was evaluated by gelatin zymography analyses. MiRNAs were analyzed by miRNA expression assays. After MDA-MB-231 cells were separately transfected with Notch-1 siRNA/cDNA and miRNA mimics, the above assays were also carried out to examine potential tumor cell changes. Xenograft models were applied to evaluate the treatment potency of Luteolin in breast cancer. Results: survival, cell cycle, tube formation and the expression of Notch signaling-related proteins and mRNAs, and regulated miRNAs. After introducing Notch-1 siRNA and miRNA mimics, MDA-MB-231 cells presented with changes in miRNA levels, reduced Notch signaling-related proteins, and decreased tumor survival, invasion and angiogenesis. Conclusion: Luteolin inhibits Notch signaling by regulating miRNAs. However, the effect of miRNAs on the Notch pathway could be either Luteolin-dependent or Luteolin-independent. Furthermore, Notch-1 alteration may inversely change miRNAs levels. Our data demonstrates that Luteolin, miRNAs and the Notch pathway are critical in breast cancer development and prognosis.
Introduction
Breast cancer is the most prevalent cancer in females in the United States, and it was the leading cause of cancer death in women aged 20 to 59 years old, according to Cancer changed the life spectrum and improved the quality of life of breast cancer patients. However, a respectable number of patients diagnosed with metastatic disease at the time of initial visit continue to suffer from poor clinical outcomes. Therefore, these patients survival. Among all strategies, therapeutic options that target critical components in cancer evolvement and metastasis signaling have great potentials.
Notch signaling plays a pivotal role in cell-fate determination processes including cell maintenance, differentiation, proliferation and apoptosis; thus, it is important in breast cancer development. A previous publication reported that the combination of Notch ligands and receptors in adjacent cells could activate proteolysis of the former, which is mediated by therefore, causes the activation of HES/HEY; which maintains stem cells by inhibiting cell differentiation [2] . A few other studies have also revealed an uncontrollable Notch receptor expression in human solid tumors such as hepatocellular carcinoma, prostate cancer, cervical cancer, non-small cell lung cancer, and osteosarcoma [3] [4] [5] [6] [7] [8] . All above evidences suggest that Notch signaling could potentially contribute to the development and progression of breast cancer, and the inhibition of the Notch pathway could possibly be a valuable treatment strategy.
non-coding single-stranded RNAs that suppress target homologous mRNA translation by base pair binding to their 3' untranslated region and inhibit protein synthesis [9] . MiRNAs are implicated in various cellular processes such as cell metabolism and immunoregulation, and have been revealed to be abnormally expressed in different kinds of tumors. Therefore, they are commonly applied in cancer diagnosis, treatment and prognosis [10] . Wang et al. reported that cross-talk between miRNAs and Notch signaling contributed to tumor development [11] . Meanwhile, other studies have also provided evidence that miR-34a was involved in regulating the p53 and Notch pathway [12, 13] . The above results suggests a in investigating new therapeutic targets that aim at Notch signaling and the downregulation of miRNAs for breast cancer.
introducing cell cycle inhibition and apoptosis in vitro; and thus, achieving anticancer effects. Other studies have also addressed that Luteolin could suppress vascular formation Our preliminary data revealed that Luteolin has a potential of inhibiting breast cancer cells by altering the expression of Notch-1 and miR-34a. Thus, we propose that a cross-talk among Luteolin, the Notch pathway and miRNAs could exist; and that this network contributes to the regulation of breast cancer development and prognosis. In the present study, we evaluated the ability of Luteolin in modulating breast cancer cell survival, migration, invasion and Notch signaling after Luteolin intervention, and illustrated their possible underlying mechanism and regulation loop. 
Results

Luteolin inhibited breast cancer cell survival
mol/L of Luteolin remarkably alter tumor cell survival.
Luteolin decreased breast cancer cell migration
Wound-healing tests revealed that scratches in cells treated with Luteolin remained larger number of cells migrated to the lower chamber in the control group compared with tumor cell survival, invasion and angiogenesis were suppressed; while the overexpression invasion, migration and angiogenesis. MiRNA has been acknowledged to be an endogenous transcriptional regulatory factor, studies have shown that miRNAs control tumor development and progression by regulating the expression and transcription of tumor-associated genes and various tumor cells that many solid tumors, and was responsible for tumor progression, compromised treatment effect and decreased survival rate [39] [40] [41] . These miRNAs also presented suppressing effects downregulated; however, opposite outcomes could be observed when miRNAs were upregulated, leading to Notch pathway alteration [42, 43] . The absence of miR-181a and miR-139-5p were revealed in different cancers such as hepatocellular carcinoma and gastric cancers [44, 45] . However, if these two factors are introduced into breast cancer cells, the ability of invasion and to enhance chemosensitivity in breast cancer treatment. Another critical component that regulates tumor progression is miRneuroblastoma and prostate, bladder and cervical cancers [48] [49] [50] [51] . It was also found that neuroglia cells and pancreatic cancer cells, illustrating that components in the Notch pathway could be downstream factors of miR-34a [12, 52] .
decreased Notch-1 levels simultaneously after applying Luteolin; thus, further experiments were carried out to illustrate the inhibiting effect of Luteolin on other components in the Our results revealed an increased expression of several barely seen miRNAs in breast cancer treatment. Moreover, transfected miR-34a or miR-224 mimics directly led to reduced Notch-1 levels, illustrating that Luteolin inhibited Notch signaling by regulating miRNAs. Nonetheless, according to our study, the interaction between miRNA and Notch-1 is not monodirectional. Notch-1 silencing could also cause decreased miR-155 levels and increased miR-34a, miRprovided inverse signal feedback, and thus, bidirectionally interacted with miRNAs. The angiogenesis; indicating that miRNAs could be independent from both Luteolin and Notch signaling, and directly alters cancer development and progression. the Notch pathway. The effect of miRNAs on Notch-1 could be introduced by Luteolin. However, it may also be Luteolin-independent. MiRNAs led to tumor suppression through above evidences demonstrate the critical status of Luteolin, miRNAs and the Notch pathway, suggesting that any components within the network could be a potential target for future treatment and drug delivery. 
